Literature DB >> 7590666

Vitamin E therapy of acute CCl4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding.

S L Liu1, S Degli Esposti, T Yao, A M Diehl, M A Zern.   

Abstract

Oxidative stress, with reactive oxygen intermediate formation, may represent a common mechanism by which liver injury is induced by diverse etiologies. Oxidative stress enhances nuclear factor kappa B (NF-kappa B) activity, and NF-kappa B activity has been shown to enhance the expression of cytotoxic cytokines. Acute hepatic injury caused by reactive oxygen intermediate production was induced by an intraperitoneal injection of CCl4 in mice. This injury was significantly inhibited by intravenous pretreatment of the mice with a water-soluble emulsion of alpha-tocopherol. Alpha-tocopherol treatment of the mice given the CCl4 also reduced the NF-kappa B binding to levels approaching those found in normal mice. In vitro treatment of a monocyte/macrophage cell line with CCl4 led to enhanced NF-kappa B binding and an increase in tumor necrosis factor-alpha (TNF-alpha) messenger RNA levels. Liver specimens taken from patients with acute fulminant hepatitis had markedly increased NF-kappa B binding activity in comparison with the binding of normal livers. These data demonstrate that abolishing acute hepatic injury with alpha-tocopherol, a free radical scavenger, also eliminated increased NF-kappa B binding. It is tempting to speculate that enhanced NF-kappa B expression caused by free radical production/oxidative stress may modulate liver injury, perhaps through an effect on cytotoxic cytokine synthesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7590666

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  21 in total

1.  The beneficial effect of N-acetylcysteine and ciprofloxacin therapy on the outcome of ischemic fulminant hepatic failure.

Authors:  Nimer Assy; Hana Gefen; Sorina Schlesinger; Osamah Hussein
Journal:  Dig Dis Sci       Date:  2007-12       Impact factor: 3.199

Review 2.  Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications.

Authors:  A P Bolger; S D Anker
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

3.  Sulforaphane inhibits mitochondrial permeability transition and oxidative stress.

Authors:  Tiffany Greco; Jonathan Shafer; Gary Fiskum
Journal:  Free Radic Biol Med       Date:  2011-09-21       Impact factor: 7.376

Review 4.  The use of selected nutrition supplements and complementary and alternative medicine in liver disease.

Authors:  A James Hanje; Brett Fortune; Ming Song; Daniell Hill; Craig McClain
Journal:  Nutr Clin Pract       Date:  2006-06       Impact factor: 3.080

5.  Deficient liver regeneration after carbon tetrachloride injury in mice lacking type 1 but not type 2 tumor necrosis factor receptor.

Authors:  Y Yamada; N Fausto
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

6.  Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride.

Authors:  J Shi; K Aisaki; Y Ikawa; K Wake
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

7.  Hepatoprotective and anti-inflammatory activities of Plantago major L.

Authors:  Idris Türel; Hanefi Ozbek; Remzi Erten; Ahmet Cihat Oner; Nureddin Cengiz; Orhan Yilmaz
Journal:  Indian J Pharmacol       Date:  2009-06       Impact factor: 1.200

8.  Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats.

Authors:  Haim Shirin; Efrat Sharvit; Hussein Aeed; Dov Gavish; Rafael Bruck
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

9.  Vitamin E attenuates liver injury induced by exposure to lead, mercury, cadmium and copper in albino mice.

Authors:  Atef M Al-Attar
Journal:  Saudi J Biol Sci       Date:  2011-08-05       Impact factor: 4.219

Review 10.  Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer.

Authors:  Lorne J Hofseth
Journal:  Cancer Lett       Date:  2008-04-25       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.